Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy

Dermatology

Volumn 218, Issue 2, 2009, Pages 146-150

  Costanzo, Antonio ^a   Talamonti, Marina ^a   Spallone, Giulia ^a   Botti, Elisabetta ^a   Chimenti, Maria Sole ^a   Papoutsaki, Marina ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Efalizumab; Generalized inflammatory flare

Indexed keywords

CYCLOSPORIN; EFALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; CYCLOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 59049097743     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000168086     Document Type: Article

References (27)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004;9:136-139.
2. Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-496.
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
4. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y: The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-392.
5. Tristani-Firouzi P, Krueger GG: Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61(suppl):11-21.
6. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-2013.
7. Kuypers TW, Roos D: Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 1989;140:461-486.
8. Dustin ML, Springer TA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-331.
9. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-4995.
10. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208:297-306.
11. Krueger GG: Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther 2002;2:431-441.
12. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
13. Barde C, Thielen AM, Saurat JH: Infliximab then efalizumab, the 'hit and run' approach does not work. Dermatology 2008;216:171-172.
14. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D: Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006;54(suppl 1):S171-S181.
15. Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
16. Cather JC, Menter A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003;3:361-370.
17. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB: Efalizumab: results of a three-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107-1116.
18. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group: Clinical experience acquired with the efalizumab (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-181.
19. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-433.
20. Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, Chimenti S: Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007;156(suppl 2):17-23.
21. Leonardi CL: Efalizumab in the treatment of psoriasis. Dermatol Ther 2004;17:393-400.
22. Scheinfeld N: Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209.
23. Hamilton TK: Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005;24:19-27.
24. Selenko-Gebauer N, Karlhofer F, Stingl G: Efalizumab in routine use: a clinical experience. Br J Dermatol 2007;156(suppl 2):1-6.
25. Ulmer A, Woelbing F, Metzler G, Schanz S, Fierlbeck G, Roecken M: Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management. Br J Dermatol 2008;158:867-869.
26. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM; Efalizumab Study Group: Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007;46:637-648.
27. Gisondi P, Giglio MD, Girolomoni G: Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatol Treat 2006;17:172-175.